Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Medtronic
McKinsey
Baxter
Harvard Business School

Last Updated: December 6, 2022

Latanoprost; netarsudil dimesylate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic drug sources for latanoprost; netarsudil dimesylate and what is the scope of freedom to operate?

Latanoprost; netarsudil dimesylate is the generic ingredient in one branded drug marketed by Aerie Pharms Inc and is included in one NDA. There are fifteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Latanoprost; netarsudil dimesylate has fifty-nine patent family members in nine countries.

One supplier is listed for this compound.

Summary for latanoprost; netarsudil dimesylate
International Patents:59
US Patents:15
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
DailyMed Link:latanoprost; netarsudil dimesylate at DailyMed
Pharmacology for latanoprost; netarsudil dimesylate
Paragraph IV (Patent) Challenges for LATANOPROST; NETARSUDIL DIMESYLATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ROCKLATAN Ophthalmic Solution latanoprost; netarsudil dimesylate 0.005%/0.02% 208259 2 2021-12-20

US Patents and Regulatory Information for latanoprost; netarsudil dimesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aerie Pharms Inc ROCKLATAN latanoprost; netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208259-001 Mar 12, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Aerie Pharms Inc ROCKLATAN latanoprost; netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208259-001 Mar 12, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Aerie Pharms Inc ROCKLATAN latanoprost; netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208259-001 Mar 12, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for latanoprost; netarsudil dimesylate

Country Patent Number Title Estimated Expiration
European Patent Office 3053913 DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE See Plans and Pricing
European Patent Office 2424857 DUAL-ACTION INHIBITORS AND METHODS OF USING SAME See Plans and Pricing
Australia 2018202990 Combination therapy See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for latanoprost; netarsudil dimesylate

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3053913 2020C/510 Belgium See Plans and Pricing PRODUCT NAME: RHOKIINSA - NETARSUDIL; AUTHORISATION NUMBER AND DATE: EU/1/19/1400 20191121
3053913 122020000016 Germany See Plans and Pricing PRODUCT NAME: NETARSUDIL, ODER EIN ENANTIOMER, DIASTEREOMER, SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/19/1400 20191119
3461484 132021000000068 Italy See Plans and Pricing PRODUCT NAME: COMBINAZIONE DI LATANOPROST E NETARSUDIL(ROCLANDA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1502, 20210108
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Mallinckrodt
Moodys
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.